Royce & Associates reports 5.81% stake in OptimizeRx
OptimizeRx Corp is reported to have a significant shareholder, Royce & Associates, LP, which files as a New York corporation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OptimizeRx Corp is reported to have a significant shareholder, Royce & Associates, LP, which files as a New York corporation. Royce reports beneficial ownership of 1,089,398 shares of OptimizeRx common stock, representing 5.81% of the class as of June 30, 2026.
Royce has sole voting and sole dispositive power over all of these shares and no shared power. The position is held for investment management clients of Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of OptimizeRx. Royce disclaims any pecuniary interest and that it is part of a “group” with Franklin affiliates or their principal shareholders.
Key Figures
Key Terms
beneficial owner regulatory
sole voting power financial
sole dispositive power financial
investment discretion financial
informational barriers regulatory
group regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of OptimizeRx (OPRX) does Royce & Associates hold?
Are Royce & Associates’ OptimizeRx (OPRX) holdings intended to influence control of the company?
Who ultimately owns Royce & Associates’ OptimizeRx (OPRX) position?
Is Royce & Associates part of a group regarding its OptimizeRx (OPRX) stake?
AI-generated analysis. How Rhea-AI works. Not financial advice.